Detalles de la búsqueda
1.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Ann Surg Oncol
; 31(6): 3872-3879, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353798
2.
Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
BJU Int
; 2024 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38886979
3.
Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.
Future Oncol
; 20(12): 781-798, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38275149
4.
Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
Int J Urol
; 31(6): 662-669, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38424729
5.
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Int J Urol
; 31(4): 362-369, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38148124
6.
Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
Int J Urol
; 30(11): 1029-1034, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37501328
7.
Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Int J Urol
; 30(2): 139-146, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36305673
8.
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Cancer Sci
; 113(7): 2386-2396, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35485635
9.
Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
Anticancer Drugs
; 33(1): e541-e547, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34387597
10.
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study.
Jpn J Clin Oncol
; 52(9): 1056-1061, 2022 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35662340
11.
Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.
Int J Clin Oncol
; 27(2): 418-426, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779962
12.
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.
Int J Clin Oncol
; 27(10): 1632-1643, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35948732
13.
Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.
Int J Clin Oncol
; 27(1): 194-201, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34599725
14.
Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Int J Urol
; 29(1): 26-32, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34549837
15.
Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
Int J Urol
; 29(10): 1147-1154, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35613936
16.
Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study.
Int J Urol
; 29(11): 1271-1278, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35855586
17.
Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
Int J Urol
; 29(5): 398-405, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080069
18.
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Cancer Sci
; 112(9): 3616-3626, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34145921
19.
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Cancer Sci
; 112(4): 1524-1533, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159829
20.
Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
Cancer Invest
; 39(3): 251-256, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33393849